What Makes AIM’s IMTBC Even More Valuable
AIM at Melanoma’s major research project, the International Melanoma Tissue Bank Consortium (IMTBC), is the first collaborative fresh frozen primary…
Melanoma Research
01/26/2023
What Makes AIM’s IMTBC Even More Valuable
AIM at Melanoma’s major research project, the International Melanoma Tissue Bank Consortium (IMTBC), is the first collaborative fresh frozen primary…
|
12/08/2022
Replimune Announces Positive Initial Data from the Anti-PD1 Failed Melanoma Cohort of the IGNYTE Clinical Trial & an RP2/3 Program Update
December 07, 2022 07:00 ET | Source: Replimune Group Inc RP1 combined with nivolumab continues to demonstrate deep and durable responses in…
|
|
11/11/2022
Iovance Biotherapeutics Announces Updated Clinical Data for Lifileucel in Advanced Melanoma at Society for Immunotherapy of Cancer (SITC) Annual Meeting
(November 07, 2022 08:01 ET | Source: Iovance Biotherapeutics, Inc. ) Clinically Meaningful and Durable Activity in Largest Cell Therapy…
|
|
05/25/2022
Interview with Dr. Zeynep Eroglu, Medical Oncologist, Moffitt Cancer Center
Dr. Zeynep Eroglu is a medical oncologist at Moffitt Cancer Center in Florida. Dr. Eroglu’s research interests are translational and…
|
05/25/2022
FAQ and Update on AIM at Melanoma’s International Melanoma Tissue Bank Consortium
TISSUE IS THE ISSUE AIM at Melanoma’s major research initiative—the International Melanoma Tissue Bank Consortium (IMTBC)—is the first of its…
|
05/25/2022
COVID-19 Has Created a Backlog of Undiagnosed Cancers, Including Melanoma
By Erin Bekes In a study by Dr. Antoine Eskander and colleagues described in the Journal of the National Comprehensive…
|
12/04/2021
FDA Approves KEYTRUDA for Stage IIB and IIC Melanoma Patients
December 4, 2021 (Richmond, California) Yesterday, Merck announced that the U.S. Food and Drug Administration (FDA) has approved Keytruda…
|
|
10/07/2021
Relatlimab/Nivolumab Application for Frontline Advanced Melanoma Validated by EMA
October 1, 2021 Kristi Rosa REPOST from OncLive The European Medicines Agency has validated its marketing authorization application for the…
|
|
09/27/2021
Vaccines 2021—Major Advances in Preventing Death from Infection and Malignancy
By Kim Margolin, M.D., FACP, FASCO Vaccine background and brief history The word “vaccine” comes from the Latin word vacca…
|
|
09/20/2021
Immunotherapy treatment may be appropriate for patients with earlier stages of melanoma
Source: University of Pittsburgh (September 20, 2021) An immunotherapy called pembrolizumab reduced cancer recurrence after surgery in patients with stage…
|
|
